CDX-1307
Our Lead Cancer program using the APC Technology
Our lead APC Targeting Technology product candidate, CDX-1307, is in development for the treatment of colorectal, pancreatic, bladder and breast cancers that express the beta chain of human chorionic gonadotropin, known as βhCG, an antigen often found in tumors of these types of cancer. The presence of βhCG in these cancers correlates with a poor clinical outcome, suggesting that this molecule may contribute to tumor growth. Normal adult tissues have minimal expression of βhCG, therefore, targeted immune responses are not expected to generate significant side effects.
| Tissue of Origin | βhCG – a prognostic indicator | βhCG –Expression |
|---|---|---|
Bladder |
Yes | 30-76% |
Colorectal |
Yes | 17-54% |
Breast |
No/Yes | 19-80% |
Pancreas |
Yes | 42% |
Renal |
Yes | 23% |
Cervical |
Yes | 26-35% |
Ovarian |
Yes | 36-41% |
Lung |
Yes | 14-93% |
- Eighteen (18) patients who presented with colorectal, pancreatic or bladder cancers have been treated in a phase I multicenter clinical trial of CDX-1307 at the Duke Comprehensive Cancer Center, Henry FordHealth System, and .Piedmont Oncology Specialists. The immunotherapy has been well tolerated, and one patient with pancreatic cancer demonstrated a reduction in tumor burden, with only minor drug-related adverse events observed (generally, reddening and/or irritation at the injection site).
- In addition, investigators at the Duke Comprehensive Cancer Center working together with us were awarded a two year $500,000 grant from the Avon Foundation and the National Cancer Institute for a Phase I clinical trial in breast cancer of intravenous CDX-1307. This trial has enrolled seven (7) patients to date without significant drug-related adverse events.
